Excellence list | TTM Capital was awarded "2022 Annual Emerging Investment Institution in Healthcare"
On April 3, 2023, HaoYue Capital, an investment institution focusing on China's healthcare industry, officially released the "2023 7th Healthcare Investment Excellence List." TTM Capital was awarded "2022 Emerging Investment Institution in Healthcare."
On April 3, 2023, HaoYue Capital, an investment institution focusing on China's healthcare industry, officially released the "2023 7th Healthcare Investment Excellence List." TTM Capital was awarded "2022 Emerging Investment Institution in Healthcare."
The "The 7th Healthcare Investment Excellence List" comprehensively reviews investment institutions in five major sectors: innovative pharmaceuticals, innovative medical devices, IVD and life sciences, medical services, and smart healthcare. Based on indicators such as investment activity, transaction volume, transaction amount, and investment returns, it selects outstanding investment institutions annually. Over the past seven years, it has become an important barometer for assessing the brand influence and market value of investment institutions. In addition, this year's Excellence List will also include law firms, accounting firms, virtual data rooms, and other related industries that provide upstream and downstream services for the healthcare industry in the selection scope.
TTM Capital was established in 2020. Since its inception, TTM Capital has always adhered to a development path that is professional, scientific, standardized, and institutionalized. The founders of the fund have an average of over 15 years of experience in the medical industry, with educational backgrounds from well-known domestic and international medical institutions and executive experience in globally renowned multinational pharmaceutical companies.
TTM Capital completed the first phase of its RMB fund raising on March 23, 2023, and received oversubscription, with a total subscription scale of nearly 1 billion RMB. The first phase of the fund will mainly focus on investments in the fields of biopharmaceuticals, medical devices, and in vitro diagnostics driven by cutting-edge technology.
TTM adheres to the "fund + incubator" special mode, leveraging cutting-edge technology and industry research to identify high-value investment targets, implementing a scientific and standardized investment decision-making mechanism and providing in-depth post-investment value-added support, committed to empowering invested enterprises and creating collaborative value, jointly promoting medical innovation and continuously creating value for society.
About XinThera Pharmaceuticals, Inc
XinThera was established in 2021, based on a structural drug discovery platform, focusing on fast follow small molecule drug development for First-in-Class and blockbuster drugs. Since receiving seed round financing in February 2021, the company has rapidly developed its business. The company was co-founded by Dr. Qing Dong, former Chief Scientist at Hengrui Pharmaceuticals, and seasoned entrepreneurs who had successfully started four companies in the U.S. and built several NASDAQ-listed companies. The R&D team consists of senior oncology and immunology experts with over twenty years of experience in new drug development, having successfully developed seven marketed drugs and a dozen clinical candidates.
Who we are
TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies. TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.
